Anti-FLIP Antibody, clone 2K7 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

CASP8 and FADD-like apoptosis regulator (UniProt: O15519; also known as Caspase homolog (CASH), Caspase-eight-related protein (Casper), Caspase-like apoptosis regulatory protein (CLARP), Cellular FLICE-like inhibitory protein (c-FLIP), FADD-like antiapoptotic molecule 1 (FLAME-1), Inhibitor of FLICE (I-FLICE), MACH-related inducer of toxicity (MRIT), Usurpin, CASP8 and FADD-like apoptosis regulator subunit p43, CASP8 and FADD-like apoptosis regulator subunit p12) is encoded by the CFLAR (also known as CASH, CASP8AP1, CLARP, MRIT) gene (Gene ID: 8837) in human. The CASP8 and FADD-like apoptosis regulator (FLIP) is a protein involved in modulating apoptosis and necroptosis pathways, primarily through its interaction with caspase-8 and FADD at the death-inducing signaling complex (DISC). Structurally similar to caspase-8, FLIP lacks enzymatic activity but serves as a crucial regulator of cell survival and death. It is expressed in various tissues, including lymphoid tissues, and plays a role in the TNFR1 and FAS-mediated signaling pathways. FLIP has multiple isoforms, including c-FLIPL and c-FLIPS, which influence its regulatory effects. While c-FLIPL can inhibit apoptosis by forming an inactive heterodimer with procaspase-8, c-FLIPS blocks the recruitment of caspase-8 to DISC. Dysregulation of FLIP is implicated in cancer progression, autoimmune disorders, and inflammatory diseases. It is considered a therapeutic target for conditions such as nonalcoholic steatohepatitis and hepatocellular carcinoma, where its modulation can impact cell death and inflammatory responses. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Davidovich, P., et al., (2023), Cell Reports, 42(12), 113476; Ranjan, K., et al., (2016), Scientific Reports, 6, 22787).

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

KLH-conjugated linear peptide corresponding to 23 amino acids from the N-terminal half of human FLIP.

Quality Control Testing
Evaluated by Western Blotting in A-431 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected FLIP in A-431 cell lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected FLIP in C2C12 cell lysate.
Affinity Binding Assay: A representative lot of this antibody bound with FLIP peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected FLIP in human skeletal muscle tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 2K7 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects FLIP. It targets an epitope within 23 amino acids from the N-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.